Amneal Pharmaceuticals, Inc. (AMRX): Free Cash Flow
$269.93M
Year ended 2025-12-31
$127.83M
Trailing 12 months to 2026-06-30
+143.5%
3-year compound annual growth
-3.5%
5-year compound annual growth
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $269.93M | +11.0% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $243.18M | -19.6% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $302.36M | n/m | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $18.69M | -90.4% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $194.09M | -39.8% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $322.56M | n/m | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | -$45.48M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $167.14M | +19.9% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $139.42M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$7.70M | n/a | 2019-03-01, From 2016-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $269.93M | +11.0% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.04B | -3.7% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $724.96M | +48.7% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $465.38M | n/m |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$307.45M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $145.10M | -40.7% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.30B | -4.5% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $284.00M | -27.9% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $702.34M | n/m |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗